The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Summary of treatment-emergent renal events from patients treated with single-agent carfilzomib from four phase II studies in relapsed and/or refractory multiple myeloma.
R Donald Harvey
No relevant relationships to disclose
Sagar Lonial
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Merck; Millennium; Novartis; Onyx
Priti Patel
Employment or Leadership Position - Onyx
Stock Ownership - Onyx
Leanne McCulloch
Employment or Leadership Position - Onyx
Ruben Niesvizky
Consultant or Advisory Role - Onyx
Research Funding - Onyx
Jonathan L. Kaufman
Consultant or Advisory Role - Celgene; Millennium; Novartis; Onyx
Honoraria - Celgene; Millennium; Novartis; Onyx
Research Funding - Celgene; Merck; Novartis; Onyx (B)